Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

Kidney Int. 2014 Apr;85(4):723-7. doi: 10.1038/ki.2013.506.

Authors

Steven J Rosansky¹, Richard J Glassock²

Affiliations

¹ Dorn Research Institute, WJBD VA Hospital, Columbia, South Carolina, USA.
² Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

PMID: 24682115
DOI: 10.1038/ki.2013.506

No abstract available

Publication types

Editorial

MeSH terms

Biomarkers
Drug Therapy
Endpoint Determination
Glomerular Filtration Rate*
Humans
Kidney Failure, Chronic / prevention & control*
Randomized Controlled Trials as Topic*

Substances

Biomarkers